Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment ...
12h
CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces the signing of a letter of intent (LOI) for the ...
Communiqué de la société OXURION du 18/03/2025 - Oxurion signs a letter of intent for the planned acquisition of a biometrics-focused CRO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback